[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100506821":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":48,"centralContacts":53,"locations":59,"responsibleParty":212,"collaborators":11,"id":214,"slug":215,"hasResults":216,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":11,"eligibilityCriteria":220,"healthyVolunteers":216,"sex":221,"minAge":222,"maxAge":11,"enrollmentInfo":223,"targetDuration":11,"studyType":226,"phases":227,"briefSummary":229,"conditions":230,"keywords":11,"overallStatus":76,"whyStopped":11,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":247},{"fullName":5,"class":6},"Orbus Therapeutics, Inc.","INDUSTRY",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Eflornithine Dose Level 1 + Temozolomide","EXPERIMENTAL",null,[13,14],"Drug: Eflornithine (Dose Level 1)","Drug: Temozolomide",{"label":16,"type":10,"description":11,"interventionNames":17},"Eflornithine Dose Level 2 + Temozolomide",[18,14],"Drug: Eflornithine (Dose Level 2)",{"label":20,"type":10,"description":11,"interventionNames":21},"Eflornithine Dose Level -1 + Temozolomide",[22,14],"Drug: Eflornithine (Dose Level -1)",[24,31,36,41],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Eflornithine (Dose Level 1)","Eflornithine 2.3 g\u002Fm2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule",[9],[30],"DFMO",{"type":25,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"Eflornithine (Dose Level 2)","Eflornithine 2.8 g\u002Fm2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule",[16],[30],{"type":25,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"Eflornithine (Dose Level -1)","Eflornithine 1.75 g\u002Fm2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule",[20],[30],{"type":25,"name":42,"description":43,"armGroupLabels":44,"otherNames":45},"Temozolomide","Temozolomide 150 mg\u002Fm2 (with option to escalate per USPI maintenance phase instructions) administered orally once daily on a 5 days on, 23 days off schedule",[20,9,16],[46,47],"Temodar","TMZ",[49],{"name":50,"affiliation":51,"role":52},"Howard Colman, MD, PhD","Huntsman Cancer Institute\u002F University of Utah","PRINCIPAL_INVESTIGATOR",[54],{"name":55,"role":56,"phone":57,"phoneExt":11,"email":58},"Monika Varga","CONTACT","6506569424","monika.varga@orbustherapeutics.com",[60,74,96,115,132,151,172,192],{"facility":61,"status":62,"city":63,"state":64,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":11},"University of Alabama at Birmingham","WITHDRAWN","Birmingham","Alabama","35294","United States","US",{"type":69,"coordinates":70},"Point",[71,72],-86.80249,33.52066,{"lat":72,"lon":71},{"facility":75,"status":76,"city":77,"state":78,"zip":79,"country":66,"countryCode":67,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Henry Ford Hospital","RECRUITING","Detroit","Michigan","48202",{"type":69,"coordinates":81},[82,83],-83.04575,42.33143,{"lat":83,"lon":82},[86,90,94],{"name":87,"role":56,"phone":88,"phoneExt":11,"email":89},"Meghan Gauronskas","313-725-7871","mgauron1@hfhs.org",{"name":91,"role":56,"phone":92,"phoneExt":11,"email":93},"Angela Dunn","313-725-7870","adunn6@hfhs.org",{"name":95,"role":52,"phone":11,"phoneExt":11,"email":11},"Tobias Walbert, MD, PhD, MPH",{"facility":97,"status":76,"city":98,"state":98,"zip":99,"country":66,"countryCode":67,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"Columbia University Medical Center - Herbert Irving Pavilion","New York","10032",{"type":69,"coordinates":101},[102,103],-74.00597,40.71427,{"lat":103,"lon":102},[106,110,114],{"name":107,"role":56,"phone":108,"phoneExt":11,"email":109},"Maria Diaz, MD","212-342-0571","md4157@cumc.columbia.edu",{"name":111,"role":56,"phone":112,"phoneExt":11,"email":113},"Nurse Navigators","212-342-5162","cancerclinicaltrials@cumc.columbia.edu",{"name":107,"role":52,"phone":11,"phoneExt":11,"email":11},{"facility":116,"status":76,"city":117,"state":118,"zip":119,"country":66,"countryCode":67,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"Duke University","Durham","North Carolina","27710",{"type":69,"coordinates":121},[122,123],-78.89862,35.99403,{"lat":123,"lon":122},[126,130],{"name":127,"role":56,"phone":128,"phoneExt":11,"email":129},"Erin Severance","919-668-6230","erin.k.bell@duke.edu",{"name":131,"role":52,"phone":11,"phoneExt":11,"email":11},"Annick Desjardins, MD, FRCPC",{"facility":133,"status":76,"city":134,"state":135,"zip":136,"country":66,"countryCode":67,"cosmosGeoPoint":137,"geoPoint":141,"contacts":142},"The Cleveland Clinic","Cleveland","Ohio","44195",{"type":69,"coordinates":138},[139,140],-81.69541,41.4995,{"lat":140,"lon":139},[143,147,150],{"name":144,"role":56,"phone":145,"phoneExt":11,"email":146},"David Peereboom, MD","216-445-6068","peerebd@ccf.org",{"name":148,"role":56,"phone":11,"phoneExt":11,"email":149},"Rachel Hufsey, RN","hufseyr@ccf.org",{"name":144,"role":52,"phone":11,"phoneExt":11,"email":11},{"facility":152,"status":76,"city":153,"state":154,"zip":155,"country":66,"countryCode":67,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"Brown University Health\u002FRhode Island Hospital","Providence","Rhode Island","02903",{"type":69,"coordinates":157},[158,159],-71.41283,41.82399,{"lat":159,"lon":158},[162,166,170],{"name":163,"role":56,"phone":164,"phoneExt":11,"email":165},"Nuno Rodrigues, RN","401.444.3059","Nuno.Rodrigues@brownhealth.org",{"name":167,"role":56,"phone":168,"phoneExt":11,"email":169},"Gada Alam","401-444-6217","GAlam@brownhealth.org",{"name":171,"role":52,"phone":11,"phoneExt":11,"email":11},"Eric Wong, MD",{"facility":173,"status":76,"city":174,"state":175,"zip":176,"country":66,"countryCode":67,"cosmosGeoPoint":177,"geoPoint":181,"contacts":182},"UT MD Anderson Cancer Center","Houston","Texas","77030",{"type":69,"coordinates":178},[179,180],-95.36327,29.76328,{"lat":180,"lon":179},[183,187,191],{"name":184,"role":56,"phone":185,"phoneExt":11,"email":186},"Carlos Kamiya Matsuoka, MD","713-408-3538","CKamiya@mdanderson.org",{"name":188,"role":56,"phone":189,"phoneExt":11,"email":190},"Evguenia Gachimova, RN","832-266-3519","Egachimova@mdanderson.org",{"name":184,"role":52,"phone":11,"phoneExt":11,"email":11},{"facility":193,"status":76,"city":194,"state":195,"zip":196,"country":66,"countryCode":67,"cosmosGeoPoint":197,"geoPoint":201,"contacts":202},"University of Utah, Huntsman Cancer Institute","Salt Lake City","Utah","84112",{"type":69,"coordinates":198},[199,200],-111.89105,40.76078,{"lat":200,"lon":199},[203,207,211],{"name":204,"role":56,"phone":205,"phoneExt":11,"email":206},"Rachel Kingsford","801-585-0115","rachel.kingsford@hci.utah.edu",{"name":208,"role":56,"phone":209,"phoneExt":11,"email":210},"Yuri Kida","801-646-4397","yuri.kida@hci.utah.edu",{"name":50,"role":52,"phone":11,"phoneExt":11,"email":11},{"type":213,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100506821","phase-1-evaluation-of-eflornithine-plus-temozolomide-in-patients-with-newly-diagnosed-glioblastoma-or-astrocytoma-100506821",false,"NCT05879367","Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma","An Open-label, Phase 1b Study to Evaluate the Safety and Tolerability of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma","Inclusion Criteria:\n\n* Diagnosis of World Health Organization (WHO) G4 classified GBM, IDH-wildtype (patients with GBM) or G3 astrocytoma (IDH1 or 2 mutant; CDKN2A\u002FB intact) per WHO 2021 tumor classification.\n* Completed external beam radiation therapy per standard of care.\n* Patients with GBM: Must have received at least 80% of planned daily doses of TMZ during chemoradiation. Patients with astrocytoma: Must have tolerated adjuvant TMZ treatment through at least 2 and not more than 4 cycles.\n* Adequate hematologic, renal, hepatic, and other organ function as indicated by hematology and serum chemistry testing.\n* Willing to abstain from intercourse or use acceptable contraceptive methods.\n* If taking corticosteroids, must be on a stable or decreasing dose.\n\nExclusion Criteria:\n\n* Recent history of recurrent or metastatic cancer that could confound response assessments\n* Prior systemic chemotherapy other than temozolomide during external beam radiation therapy (for patients with GBM) or adjuvant temozolomide through up to 4 pre-study cycles (for patients with astrocytoma).\n* Prior Optune treatment.\n* Active infection or serious intercurrent medical illness.\n* Poorly controlled seizures.\n* Significant cardiac disease within 6 months of enrollment.\n* Poorly controlled diabetes.\n* Use of another investigational agent within 30 days of enrollment.","ALL","18 Years",{"count":224,"type":225},66,"ESTIMATED","INTERVENTIONAL",[228],"PHASE1","The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.",[231,232,233,234,235,236,237],"Glioblastoma, IDH-wildtype","Glioblastoma","Glioblastoma Multiforme","Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype","GBM","Astrocytoma","Astrocytoma, IDH-Mutant","2025-06-19",{"date":240,"type":241},"2025-06-25","ACTUAL",{"date":243,"type":241},"2023-07-24",{"date":245,"type":225},"2026-06-30",{"name":5,"class":6},8]